Harmony Biosciences Holdings (HRMY) is a Healthcare · Biotechnology company listed on NASDAQ. Price $42.02 (-1.68%), Market cap $1.82B, P/E ratio 12.65, 52-week low–high $25.90 ~ $40.51.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under
Financial statements, price targets, institutional (13F) holdings and related news for Harmony Biosciences Holdings are updated in real time on BlackAll Trade.
Harmony Biosciences Holdings trades at $42.02 (-1.68%). Real-time quotes and charts are available on BlackAll Trade.
Harmony Biosciences Holdings has a market cap of about $1.82B. Its P/E ratio is 12.65.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. Th